Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.
Frontiers in Pharmacology 2025 Haoning Guo, Liling Tang, Miaoquan He et al. 5 citations
Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May 2025. Eligible...